Jeremy Grantham Kezar Life Sciences, Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$7.44 - $16.72 $523,173 - $1.18 Million	-70,319 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$4.85 - $9.73 $240,074 - $481,635	-49,500 Reduced 41.31%	70,319 $608,000
Q2 2021 Aug 12, 2021	SELL	$4.93 - $6.46 $15,283 - $20,026	-3,100 Reduced 2.52%	119,819 $651,000
Q1 2021 May 13, 2021	SELL	$5.24 - $6.99 $95,792 - $127,784	-18,281 Reduced 12.95%	122,919 $733,000
Q4 2020 Feb 12, 2021	BUY	$4.77 - $6.58 $353,456 - $487,578	74,100 Added 110.43%	141,200 $737,000
Q3 2020 Nov 13, 2020	BUY	$4.36 - $5.5 $222,796 - $281,050	51,100 Added 319.38%	67,100 $325,000
Q2 2020 Aug 13, 2020	BUY	$3.6 - $7.75 $57,600 - $124,000	16,000 New	16,000 $83,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $445M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.